Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027993 | 1.00 | SYK (0.50) | SYKPDE4BMAPTHTTCYP1A2 | |
| SCHEMBL9106445 | 0.94 | SYK (0.47) | SYKPDE4BMAPTHTT | |
| SCHEMBL5027991 | 0.94 | SYK (0.47) | SYKPDE4BMAPTHTT | |
| SCHEMBL10076911 | 0.86 | PDE4B (0.46) | SYKPDE4BMAPTHTTCYP1A2 | |
| SCHEMBL14909754 | 0.85 | PDE4B (0.46) | SYKPDE4BMAPTHTTCYP1A2 | |
| SCHEMBL14909803 | 0.85 | PDE4B (0.46) | SYKPDE4BMAPTHTTCYP1A2 | |
| SCHEMBL20473551 | 0.85 | PDE4B (0.46) | SYKPDE4BMAPTHTTCYP1A2 | |
| SCHEMBL14909666 | 0.84 | SYK (0.42) | SYKPDE4BMAPTHTTCYP1A2 | |
| SCHEMBL9105240 | 0.84 | SYK (0.45) | SYKMAPTHTTTLR8 | |
| SCHEMBL9105217 | 0.84 | SYK (0.45) | SYKMAPTHTTTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902688-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3176154-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9359375-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8846928-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | SYK 1/4885PDE4B 1206/4885MAPT 4538/4885 |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | SYK 1/4885PDE4B 1206/4885MAPT 4538/4885 |
| US-20150038492-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | SYK 1/4885PDE4B 1206/4885MAPT 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.